22 April 2024: Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Department
Michał Machowski 1ABCDEF , Aisha Ou-Pokrzewińska 1BCDEF , Katarzyna Perzanowska-Brzeszkiewicz 1BCDEF , Magdalena Gałecka-Nowak 1BDE , Szymon Pacho 1BDE , Mateusz Jermakow 1BCDE* , Agnieszka Wójcik 1BDE , Milena Zoruk 1BDE , Andrzej Pruszczyk 1BDE , Karol Deutsch 1BDE , Marek Roik 1BDE , Andrzej Łabyk 1BDE , Piotr Palczewski 2ABDEF , Piotr Pruszczyk 1ABCDEFDOI: 10.12659/MSM.942612
Med Sci Monit 2024; 30:e942612
Table 2 Clinical characteristics according to the diagnosed acute cardiovascular disease.
| Parameter [unit] | ACS (n=40) | APE (n=42) | AMyo (n=19) | COVID-19 pneumonia only (n=148) | P-value | Post-hoc |
|---|---|---|---|---|---|---|
| Age [years] | 71.8 (11.3) | 70.6 (12.3) | 64.2 (21.1) | 66. 9 (13.6) | 0.074*** | |
| CAD, n (%) | 16 (40.0) | 6 (14.3) | 10 (52.6) | 28 (18.9) | * | |
| CHF, n (%) | 10 (25.0) | 3 (7.1) | 9 (47.4) | 29 (19.6) | 0.004** | |
| COVID-19 pneumonia lung involvement [%] | 33.6 (26.0) | 54.1 (23.9) | 45.2 (22.9) | 52.7 (24.3) | 0.005*** | ACS |
| Procalcytonin [ng/ml] | 0.20 (0.07;0.4) | 0.14 (0.07;0.3) | 0.42 (0.27;0.9) | 0.18 (0.08;0.4) | 0.245**** | |
| CRP [mg/dl] | 43.3 (9.3;87.7) | 72.3 (38.1;165.4) | 67.4 (39.57;157.0) | 93.9 (40.4;161.3) | 0.005**** | ACS |
| MEWS | 1.0 (0.0;2.0) | 1.0 (1.0;2.0) | 2.0 (1.0;3.0) | 2.0 (1.0;2.0) | 0.081**** | |
| ACS – acute coronary syndrome; AMyo – acute myocarditis; APE – acute pulmonary embolism; CAD – coronary artery disease; CHF – congestive heart failure; CRP – C-reactive protein; MEWS – Modified Early Warning Score. Groups compared with: * chi-square test, ** Fisher exact test, *** ANOVA, **** Kruskal-Wallis test. For ANOVA, Tukey post-hoc test was used, for Kruskal-Wallis test, Dunn post-hoc test was used (with Bonferroni correction). | ||||||